Posted by Michael Wonder on 12 Nov 2022
European Commission approves Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus infection and/or disease that are refractory (with or without resistance) to one or more prior therapies
11 November 2022 - Livtencity is the first and only treatment approved for this indication by the EC.
Takeda today announced that the European Commission has granted marketing authorisation for Livtencity (maribavir) for the treatment of cytomegalovirus infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet, in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant.
